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Gait and balance disturbances are major concerns for 
older people and have been related to multiple factors 
and disorders [1–5]. Cerebral small vessel disease (SVD) 
has been particularly implicated in the etiology of gait 
problems [6–8]. In a cross-sectional study of community-
dwelling healthy older people we found that brain 
volume  and white matter hyperintensity (WMH) volume 
 
were each independently associated with gait speed [9]. 
Furthermore, WMH burden was the major contributor 
for gait impairment within a global SVD score, com-
prising WMH, microbleeds, lacunes and enlarged 
perivascular spaces [9]. Associations between the same 
brain variables and chair-stands or balance function 
were limited, possibly due to either a low impact of 
SVD or the low sensitivity of these applied tests in 
healthy older people.  
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Studies investigating the role of SVD in a longitudinal 
manner showed that initial WMH burden was 
associated with the subsequent development and 
severity of gait and balance dysfunction [7,10–16].  
 
Only a few studies have investigated the association of 
WMH progression with increasing gait or mobility 
dysfunction [10,17,18]. In one study of 104 cognitively 
intact individuals aged 65 and older, WMH progression 
was associated with decreased gait performance over 
time, but no association with balance function was 
reported [17]. By contrast, in a study of 77 community-
dwelling individuals aged 75 and older, WMH progress-
sion correlated with decreased mobility performance 
changes assessed by the chair-stands test, but not with 
gait [18]. A large longitudinal population-based study in 
225 individuals aged 60 to 86 showed that WMH 
increase and brain atrophy were associated with gait 
decline [10]. These three previous longitudinal studies 
included individuals with a wide age-range of several 
decades and highlight how multiple variables, such as 
age, infarcts or brain volume, may modify associations 


































Therefore, we attempted to complement this 
information in a comprehensive analysis of longitu-
dinal data from the Lothian Birth Cohort 1936 
(LBC1936) which comprises generally healthy 
community-dwelling older people with a narrow age 
range. Based on our cross-sectional analysis [9], we 
focused specifically on the association between gait 
speed and changes in brain volume and in WMH 
volume, in addition to demographics, vascular risk 






Table 1 gives information on the demographics, 
physical, vascular risk factor variables, gait and balance 
function and MRI characteristics of the study sample at 
baseline and follow-up. Height and grip strength 
decreased over the three years of follow-up. The 
number of individuals reporting leg cramp, arthritis, 
high blood pressure, diabetes and high cholesterol 




































Demographics Baseline N=443 Follow-Up  
Sex, male, N (%) 244 (55.10)   
Age in years 72.52 (0.69) 76.29 (0.65) <0.001 
Physical factors Baseline N=443 Follow-Up p 
Height (FUP N= 442) 166.82 (8.98) 166.22 (8.92) <0.001 
Grip Strength (FUP N= 442) 29.01 (9.23) 27.69 (9.53) <0.001 
Leg cramp, N (%) 169 (38.10) 204 (46.00) <0.001 
Arthritis, N (%) 206 (46.50) 215 (48.50) <0.001 
Vascular risk factors Baseline N=443 Follow-Up p 
Smoking (current), N (%)(FUP N= 442) 30 (6.77) 28 (6.33) 0.480 
High Blood Pressure, N (%)(FUP N= 442) 219 (49.40) 249 (56.33) <0.001 
Diabetes, N (%) 42 (9.50) 55 (12.40) <0.001 
High Cholesterol, N (%) (FUP N= 440) 184 (41.50) 211 (47.95) <0.001 
BMI (FUP N= 442) 27.67 (4.07) 27.62 (4.26) 0.486 
 































Mean gait speed decreased significantly across the three 
years and the magnitude of change was on average 
about one-third of a standard deviation. At baseline 
(mean age 73), gait impairment with a walking speed 
below 1.0 m/s was observed in 5.0 % (N=22) and at 
follow-up (mean age 76) in 10.4% (N=43). Gait speed 
declined clinically significantly (≥ 0.1 m/s per year) in 
108 participants (24.4%). Performance on the chair-
stands test did not significantly change over the three 
years of follow-up, but performance on the standing 
balance test significantly decreased (p < 0.001). 
 
Brain volume significantly decreased and WMH 
volume significantly increased across the three years 
(Table 1). Brain volume change and WMH progression 
did not correlate (r = -0.032; p = 0.502). 
 
Prediction of gait speed at age 76 
 
The regression model revealed that age, grip strength and 
BMI at baseline, brain volume decrease and WMH 
increase independently contributed to the prediction of 
gait speed at age 76, explaining in total 26.1% of 
variance. Age, grip strength and BMI at baseline were the 
strongest predictors, explaining together 23% of the 































brain and WMH added little (1.6 and 1.5% respectively) 
to explaining the variance in gait speed. For further 
details please see Table 2.  
 
Prediction of changes in gait speed 
 
The regression model revealed that gait speed, grip 
strength and BMI at baseline, brain volume decrease 
and WMH increase independently contributed to 
changes in gait speed between age 73 and 76, 
explaining in total 40.9% of variance. Gait speed at 
baseline was the strongest predictor (33.1%) and 
volume changes of the brain and of WMH added little 
(1.3% and 1.1% respectively) to explaining the variance 
in gait speed (Table 3). Including duration of follow-up 
in the regression analyses did not change the results 
(data not shown). 
 
Differences of individuals with vs. without clinically 
significant gait decline 
 
Individuals with a clinically significant gait decline 
between 73 and 76 years as defined by a decrease of 
gait speed of >-0.1 m/s per year had walked faster and 
were slightly younger at baseline but showed no other 
significant differences in any of the variables assessed 
Gait Speed and Balance function Baseline Follow-Up p 
6 meter walk time (sec) 4.15 (1.01) 4.56 (1.27) <0.001 
Gait speed (m/sec) 1.52 (0.34) 1.40 (0.35) <0.001 
Chair-Stands (sec) (FUP N=420) 13.11 (3.77) 13.01 (4.13) 0.607 
Standing balance score= 4; N (%) (FUP 
N=441) 
391 (88. 30) 367 (83.22) <0.001 
Gait impairment: speed < 1.0 m/s N=22 (5.0%) N=43 (10.4%)  
MRI characteristics Baseline Follow-Up  
Brain Volume (cm³) 995.46 (92.50) 976.53 (90.53) <0.001 
WMH Volume (cm³) 11.75 (11.73) 15.62 (14.52) <0.001 
Old infarcts  53 (12.0%)   
Lacunes (1 or more) 25 (5.6%)   
PVS (grade 2-4 in BG) 176 (39.7%)   
CMB 49 (11.1%)   
Sample  characteristics  are  presented  as  mean  and  standard  deviation  (SD  in  brackets),  or  number  of 
individuals (N) and percentage (%). FUP = 3 year follow‐up, N = number of participants.  
BG= basal ganglia, CMB= cerebral microbleeds, PVS= perivascular spaces 
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(Table 4). The time interval between their baseline and 
follow-up assessment was slightly longer than that of 
individuals whose change in gait speed did not reach the 
level of a significant decline. Individuals with clinically 
significant changes in gait speed showed bigger changes 
in gait speed and also showed larger changes at the 
chair-stands test. Furthermore, individuals with a 
clinically significant gait decline showed a greater 
reduction of normalized brain volume and increase in 
WMH volume. Changes in all other variables were non-
significant (Table 4). Comparable results were obtained 
when performing these analyses after exclusion of 
individuals with gait impairment at baseline (N=22). 
 
Sensitivity analysis excluding individuals with a 
history of stroke 
 
Out of 443 individuals, 28 reported a history of stroke at 
baseline during the medical interview. In the entire 





































diction of decline in gait impairment (p = 0.106). 
Sensitivity analysis for 415 individuals without a self-
reported history of stroke revealed identical findings 
showing that age (p = 0.021; R² = 5.0 %); grip strength 
(p < 0.001; ∆R ²= 9.7 %), BMI (p < 0.001; ∆R² = 5.0 
%), brain volume change (p = 0.006; ∆R² = 1.4 %) and 
WMH increase (p = 0.001; ∆R² = 1.9%) predicted gait 
speed at mean age 76, explaining 23.0% of variance. 
Results for changes in gait speed were identical for the 
sample excluding those with a history of stroke (R² = 
47.1 %), (gait speed at baseline p < 0.001; R² = 42.3 %, 
grip strength p < 0.001; R² = 2.2 %, BMI p = 0.005; R² 
= 0.5 %, brain volume change p= 0.003; R² = 1.1 %, 




This three-year longitudinal study shows that even in 
generally healthy community-dwelling individuals with 






































Gait speed (sec) R² β (95% CI) βj p 
Gait speed (sec)* 33.1 0.449 (0.364 to 0.533) 0.434 <0.001 
Grip Strength (kg)* 36.7 (3.6) 0.008 (0.003 to 0.013) 0.221 <0.001 
BMI* 38.5 (1.8) -0.013 (-0.019 to -0.006) -0.149 <0.001 
BV Change 39.8 (1.3) 3.101 (1.104 to 5.099) 0.114 0.002 









 R² β (95% CI) βj p 
Age*  10.6 -0.082 (-0.123 to -0.041) -0.163 <0.001 
Grip Strength*  17.3 (6.7) 0.013 (0.007 to 0.018) 0.339 <0.001 
BMI*  23.0 (5.7) -0.019 (-0.026 to -0.012) -0.223 <0.001 
BV Change  24.6 (1.6) 3.4000 (1.168 to 5.633) 0.125 0.001 
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over three years were significant and independent 
predictors of gait speed and changes in gait speed. 
However, the comparatively larger impact of malleable 
physical factors such as grip strength or BMI is 
noteworthy and raises the possibility of reducing gait 
dysfunction in older adults with targeted interventions 
and of predicting gait dysfunction with simple office 
tests of grip strength.  
 
Our study more than doubles the data from previous 
longitudinal investigations on the influence of WMH 
progression on gait and balance function [10,17] and 
extends the knowledge base by including baseline gait 
performance, multiple vascular risk factors and physical 
variables. The findings suggest that in community-
dwelling older adults physical variables such as grip 
strength and BMI might be more important than brain 
structural changes, but that both contribute to change in 





































associated with faster walking at mean age 76 and 
explained 6.7% of gait impairment and 3.6% of changes 
in gait speed. Grip strength has been used as a proxy for 
global physical function, sarcopenia and frailty [19,20]. 
The promotion of muscle strength in older people might 
therefore be a target to reduce gait impairment, although 
further studies are needed in this context. Previous 
cross-sectional findings note that physical activity might 
have the potential to reduce the risk of mobility 
impairment in the older people with mild to severe 
WMH burden [21] and a recent meta-analysis including 
42 studies reports that exercise interventions can 
increase gait speed and help to slow the decrease of gait 
speed or delay its onset [22]. 
 
Furthermore, a higher BMI was related to slower 
walking at mean age 76. This finding is in line with 
findings that increasing BMI over 25 years is associated 







































Baseline age 73   p Changes  p 
 Decline 
N =108 (24.4%) 
No Decline 
N =335 (75.6%) 
 Decline No Decline  
Sex/male, N (%) 68 (62.96) 176 (52.54) 0.060 NA NA  
Age 72.23 (0.90) 72.63 (1.07) 0.004 3.82 (0.11) 3.79 (0.16) 0.015 
Physical factors       
Height 168.40 (12.75) 166.49 (13.60) 0.131 -0.50 (1.28) -0.50 (1.25) 0.552 
Grip Strength 30.50 (15.88) 29.00 (15.50) 0.394 -1.75 (5.50) -1.00 (4.38) 0.293 
Leg cramp, N(%) 39 (36.11) 130 (38.81) 0.650 21 (19.44) 59 (17.61) 0.448 
Arthritis, N(%) 51 (47.22) 155 (46.27) 0.912 8 (7.41) 32 (9.55) 0.219 
Risk factors       
Smoking, N(%) 9 (8.33) 21 (6.29) 0.615    
HBP, N(%) 49 (45.37) 170 (50.75) 0.376 7 (6.48) 32 (9.55) 0.602 
Diabetes, N(%) 12 (11.11) 30 (8.96) 0.571 5 (4.63) 9 (2.69) 0.517 
HChol, N(%) 45 (41.67) 139 (41.50) 0.975 15 (13.89) 33 (9.85) 0.481 
BMI 27.53 (4.96) 27.19 (4.84) 0.449 0.09 (1.39) 0.02 (1.72) 0.387 
Gait and Balance       
6 meter walk time 
(sec) 
3.60 (0.83) 4.33 (0.99) <0.001 1.59 (0.87) 0.23 (0.69) <0.001 
Gait speed (m/sec) 1.72 (0.52) 1.45 (0.33) <0.001 -0.46 (0.22) -0.03 (0.27) <0.001 
Chair-stands(sec) 12.07 (5.02) 13.04 (4.62) 0.051 0.29 (4.52) -0.27 (4.29) 0.002 
Standing score=4, 
N(%) 






MRI-markers       
Brain Volume* 68.94 (2.79) 69.24 (2.76) 0.173 -1.46 (0.02) -1.07 (0.01) 0.003 





www.aging‐us.com  6  AGING 
showed that a high BMI scores (over 30) is associated 
with a higher risk of developing mobility impairment 
[24]. Two longitudinal studies assessing the relationship 
between WMH increase and gait impairment included 
BMI in their regression models, but did not report if and 
to what extent BMI predicted gait impairment [10,18]. 
In addition, physical fitness, as measured by grip 
strength, lung function and six meter walk time, has 
been shown to be a protective factor for structural brain 
ageing in the LBC1936 [25]. 
 
This study also extends several previous longitudinal 
studies which investigated the impact of WMH 
progression on gait impairment and decline by mini-
mizing the confounding effects of age [7,10,11,14,17]. 
 
Callisaya et al. [10] highlight that the relative 
contribution of atrophy and WMH progression 
strengthens the causal relationship between structural 
brain changes and gait decline. However, atrophy [26], 
the burden and increase of WMH [27], the extent and 
decline of gait impairment [3,4] and their associations 
are all influenced by increased age [10]. Hence, a major 
strength of our study is the investigation of a large 
sample with a narrow age range.  
 
Both degenerative and vascular processes have been 
associated with age-related gait impairment in cross-
sectional studies [28]. Interestingly and in line with the 
only previous longitudinal study assessing brain and 
WMH volume change in relation to gait decline [10], 
we found similar but independent contributions of a 
decrease in brain volume and of WMH progression on 
gait impairment and decline. In this context it is also 
noteworthy that the decrease in brain volume and 
progression of WMH in our cohort were comparable to 
prior studies [10,18,29] of individuals with this age-
range.  
 
It is not unexpected that gait speed at baseline is 
associated with gait function three years later. In fact 
baseline gait speed was by far the strongest, positive 
predictor of gait speed at follow up. However, when 
comparing individuals with and without a clinically 
significant gait decline as defined by an annual 
reduction of gait speed of > 0.1 m/s [30,31], i.e. > 0.3 
m/s in our study, those with a significant decline had 
walked faster at baseline. While this may appear 
implausible at first, it probably attests to the fact that 
decline in gait speed is a not a fully linear phenomenon. 
Furthermore, individuals with high gait speed at 
baseline have the largest possibility for change, there-
fore the regression to the mean phenomenon should also 
be considered in this context [32]. Other significant 
differences between individuals without and with a 
significant decline in gait speed were a larger decrease in 
brain volume and increase in WMH volume in the latter. 
Individuals with a significant decline in gait speed also 
had a significantly but only slightly longer time interval 
to follow up assessment. However, including the follow-
up duration in the regression analysis did not influence 
the results of the regression analysis. 
 
Since both stroke [33] and the occurrence of WMH 
have been associated with gait impairment in older 
people, we performed sensitivity analysis excluding 
individuals reporting a history of stroke. In line with a 
previous study, history of stroke did not affect the 
impact of WMH change on gait speed and decline 
[11]. 
 
Given the major impact of gait impairment for older 
adults regarding increased mortality, risk of developing 
dementia or cardiovascular disease, risk of falling and 
functional independence predicting early gait dys-
function and decline is highly desirable [3,30]. In this 
regard our findings suggest that for prediction of gait 
function and decline in healthy older people a simple 
assessment of physical function and of vascular risk 
factors might be sufficient. Although MRI-markers such 
as changes in brain volume and WMH volume 
independently add to the explanation, the expense of an 
MRI-measurement might not be essential regarding 
prediction of gait in large samples.  
 
When interpreting our findings the specific setting of a 
healthy community-dwelling cohort with a follow-up 
duration of only 3 years and thus only small changes in 
all variables needs to be considered. The fact that we 
were able to observe significant associations of brain 
morphologic and physical factors with gait speed and its 
decline therefore attests to the robustness of this 
relation. At the same time this setting entails some 
limitation as we may have not been able to detect more 
subtle relationships with other variables which could 
impact gait speed. Likewise more sensitive and robust 







Data from community-dwelling older people who were 
members of the LBC1936 were analyzed [34,35]. More 
detailed information of the recruitment and study 
procedures can be found in Deary et al. [34,35]. We 
included only those individuals who underwent 
comprehensive risk factor assessment and gait and 
balance assessment and brain MRI acquisition at age 73 
(age range = 70.96 to 74.16 years; Wave 2 of the 
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LBC1936 study) and 76 (age range = 74.73 to 77.75 
years; Wave 3). Eight participants were excluded from 
further analyses due to a diagnosis of Parkinson’s 
disease (N=1, Wave 2; N=2 Wave 3) and/or dementia 
(N=6, Wave 3), rendering a final sample of 443 
individuals.  
 
Standard protocol approvals, registrations, and 
patient consents 
 
Ethics permission for the study protocol was obtained 
from the Multi-Centre Research Ethics Committee for 
Scotland (MREC/01/0/56) and from Lothian Research 
Ethics Committee (LREC/2003/2/29). The research was 
carried out in compliance with the Helsinki Declaration. 
All assessments were performed in accordance with 
relevant guidelines and regulations. All participants 
gave written, informed consent. 
 
Vascular risk factor assessment and physical 
examination 
 
An extensive description of all variables obtained for 
the LBC1936 study can be found in Deary et al. [35] for 
clinical and Wardlaw et al. for imaging variables [36]. 
All participants underwent a medical interview and 
physical examination (e.g. height and weight to 
calculate Body Mass Index (BMI kg/m²)). Disease 
history (e.g. self-reported history of stroke), physical 
variables (e.g. self-reported leg cramp when walking or 
in bed at night, self-reported arthritis) and vascular risk 
factors (e.g. smoking, self-reported high blood pressure, 
self-reported diagnosis of diabetes, self-reported high 
cholesterol) were obtained in a structured interview. As 
part of the physical examination we also obtained grip 
strength in the right and left hand using a North Coast 
Hydraulic Hand Dynamometer (JAMAR) and used 
overall grip strength in kg (best of three trials of the 
right and left hand) for our analyses. 
 
Assessment of gait and balance function 
Gait speed was assessed by the six-meter walk test, a 
common assessment used in research studies to access 
physical function [37]. Participants were asked to walk 
as quickly as possible with the use of a cane or walker if 
appropriate. Gait speed was measured in meters/second. 
Gait impairment was defined as a gait speed < 1.0 m/s, 
as this cut-off was suggested to identify persons with a 
high risk of health-related lower extremity limitations 
and hospitalization [30,38] and clinically significant 
gait decline was defined as >-0.1 m/s per annum, as this 
decline was related to survival rates in a large pooled 
analysis of nine cohort studies [30,31]. Furthermore, 
two subtests (chair-stands and standing balance) of the 
Short Physical Performance Battery were applied as 
described earlier [39]. In brief, the chair-stands test 
assesses how long (seconds) it takes the participant to 
stand up and sit down as quickly as possible five times 
without stopping. The test of standing balance includes 
side-by-side, semi-tandem, and tandem stands which are 
scored from 1 to 4 points, reaching 4 points indicates 
the best standing balance performance.  
 
Brain MRI acquisition 
 
The brain imaging protocol for the study has been 
described previously [36]. All participants were scanned 
on a General Electric 1.5 T clinical MRI scanner (Signa 
Horizon HDx) operating in research mode. For this 
study, we used axial T2-, T2*-, fluid-attenuated inversion 
recovery (FLAIR) and T1-weighted sequences. 
 
Assessment of brain volume and WMH volume 
 
Intracranial (ICV), whole brain, and WMH volumes 
were assessed in mL using a validated multispectral 
image processing method that combines T1-, T2-, T2*-, 
and FLAIR-weighted MRI sequences for segmentation 
[40]. All sequences were coregistered and tissue 
volumes estimated by cluster analysis of voxel 
intensities. WMH masks were manually edited by 
following Standards for Reporting Vascular changes on 
neuroimaging guidelines and using 3D-mask editing 
software, Multi-Image Analysis GUI (MANGO; 
http://ric.uthscsa.edu/mango/). Editing was overseen by 
a neuroradiologist (JMW). We manually checked all 
segmented images for accuracy blinded to all clinical 
details, corrected errors, and excluded imaging-detected 
cortical and subcortical infarcts from WMH manually. 
Brain tissue volume and WMH volume normalized by 




We used the Statistical Package of Social Science (IBM 
SPSS Statistics 23, SPSS Inc., Chicago, Illinois, USA) 
for paired t-tests, nonparametric analysis (e.g. 
McNemar and Wilcoxon Rank), correlation and 
regression analyses.  
 
A hierarchical linear regression model was used to 
assess whether gait speed at mean age 76 was 
independently predicted by changes in normalized brain 
volume and an increase in normalized WMH volume in 
addition to demographics (sex, age), baseline physical 
factors (height, grip strength, leg cramp, arthritis), and 
baseline vascular risk factors (smoking, diabetes, high 
blood pressure, high cholesterol, BMI). To assess 
whether brain volume and WMH increase 
independently predicted changes in gait speed, the same 
model was applied including gait speed at baseline 
(mean age 73) in the first step. 
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We checked for fulfilment of different assumptions for 
the regression analyses (e.g. linearity, homoscedasticity, 
auto-correlation (Durban-Watson-test), multicollinearity 
(Tolerance and Variance Inflation Factor)). Betas and 
confidence interval (CI), standardized beta-values (βj), 
adjusted R² (explanation of variance) and delta (Δ) 
adjusted R² (displaying incremental explanation of 
variance) in percent are presented for each model in the 
results section. The adjusted R² reflects R² that has been 
adjusted for the number of predictors in the model. R² 
tends to optimistically estimate the fit of the linear 
regression. It always increases as the number of 
predictors increase in the model. Therefore adjusted R² 
attempts to correct for this overestimation. Standardized 
beta coefficients put all of the variables on the same 
scale, and allows a comparison of the magnitude of the 
coefficients to see which one has the larger effect size. 
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